We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
Read MoreHide Full Article
Incyte Corporation (INCY - Free Report) reported third-quarter 2024 adjusted earnings of $1.07 per share, which missed the Zacks Consensus Estimate of $1.12. The company recorded earnings of $1.10 per share in the year-ago quarter.
Total revenues in the reported quarter were $1.14 billion, which grew 23.8% year over year, driven by the sustained performance of its lead drug, Jakafi (ruxolitinib), and increased sales of Opzelura (ruxolitinib) cream on strong launch and demand. The top line beat the Zacks Consensus Estimate of $1.09 billion.
All percentages mentioned below are on a reported basis.
Jakafi’s (a first-in-class JAK1/JAK2 inhibitor approved for polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease) revenues came in at $741.2 million, up 16% from the year-ago quarter, owing to a 10% increase in total demand. Jakafi's sales beat the Zacks Consensus Estimate of $717.5 million.
Opzelura (ruxolitinib) cream, approved for atopic dermatitis and vitiligo, generated $139.3 million in sales, which rose 52% year over year and surpassed the Zacks Consensus Estimate of $130.8 million. The year-over-year rise in sales was driven by continued growth in new patient starts and refills in the United States and increased contribution from the EU, driven by continued uptake in Germany and the launch in France.
The newly approved medicine Zynyz (retifanlimab-dlwr) generated sales of $0.69 million. The company obtained accelerated approval for Zynyz to treat metastatic or recurrent locally advanced Merkel cell carcinoma. The net product revenues of Iclusig were $29.7 million, up 7% year over year. The figure beat the Zacks Consensus Estimate of $28.1 million. Pemazyre generated $20.7 million in sales, reflecting a year-over-year decrease of 9%. The figure missed the Zacks Consensus Estimate of $22.2 million.
Minjuvi's revenues totaled $31.4 million, surging 277% from the prior-year quarter’s number, following the acquisition of the exclusive global rights to the drug in February 2024. The figure, however, missed the Zacks Consensus Estimate of $33.9 million. Incyte gained worldwide exclusive global rights for tafasitamab from MorphoSys AG, which is marketed as Monjuvi in the United States and as Minjuvi in the ex-U.S. markets in February.
Shares of Incyte have risen 4.6% year to date against the industry’s 3% decline.
Image Source: Zacks Investment Research
We remind investors that Jakafi is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets. Jakavi royalty revenues from Novartis for commercialization in ex-U.S. markets rose 20% to $115.7 million. Jakavi royalties beat the Zacks Consensus Estimate of $104.7 million.
Incyte also receives royalties from the sales of Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small-cell lung cancer. Its partner, Novartis, has exclusive worldwide development and commercialization rights for Tabrecta. The royalty revenues from the drug’s sales amounted to $5.9 million, up 43% year over year.
Olumiant’s (baricitinib) product royalty revenues from Eli Lilly (LLY - Free Report) totaled $34.8 million, up 17% year over year. The figure missed the Zacks Consensus Estimate of $35.2 million. Incyte has a collaboration agreement with Eli Lilly for Olumiant. The drug is a once-daily oral JAK inhibitor discovered by Incyte and licensed to LLY. It is approved for several types of autoimmune diseases.
Adjusted research and development expenses totaled $525.3 million, up 51% year over year. This increase was primarily due to the $100 million milestone payment made to MacroGenics during the third quarter of 2024 and continued investment in the company’s late-stage development assets.
Adjusted selling, general and administrative expenses were $277.3 million, up 15% from the prior year quarter’s number, primarily due to the timing of consumer marketing activities and that of certain other expenses. Incyte’s cash, cash equivalents and marketable securities totaled $1.8 billion as of Sept. 30, 2024, compared with $1.4 billion as of June 30, 2024.
INCY’s Updated 2024 Guidance
Incyte raised the 2024 revenue guidance for Jakafi. The company now expects Jakafi revenues in the range of $2.74-$2.77 billion compared with the earlier projection of $2.71-$2.75 billion.
Adjusted research and development expenses are now expected in the band of $2.395-$2.435 billion compared with the earlier projection of $2.295-$2.335 billion. Adjusted selling, general and administrative expenses are expected in the range of $1.115-$1.140 billion.
In August 2024, Incyte and partner Syndax Pharmaceuticals obtained FDA approval for axatilimab-csfr, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease after the failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. The candidate was approved under the brand name Niktimvo.
In the past 60 days, estimates for Fate’s 2024 loss per share have narrowed from $1.74 to $1.73. Loss per share estimates for 2025 have narrowed from $1.71 to $1.69, during the same period. Year to date, shares of FATE have lost 23.3%.
Fate’s earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 18.22%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
Incyte Corporation (INCY - Free Report) reported third-quarter 2024 adjusted earnings of $1.07 per share, which missed the Zacks Consensus Estimate of $1.12. The company recorded earnings of $1.10 per share in the year-ago quarter.
Total revenues in the reported quarter were $1.14 billion, which grew 23.8% year over year, driven by the sustained performance of its lead drug, Jakafi (ruxolitinib), and increased sales of Opzelura (ruxolitinib) cream on strong launch and demand. The top line beat the Zacks Consensus Estimate of $1.09 billion.
All percentages mentioned below are on a reported basis.
See the Zacks Earnings Calendar to stay ahead of market-making news.
INCY’s Q3 Results in Detail
Jakafi’s (a first-in-class JAK1/JAK2 inhibitor approved for polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease) revenues came in at $741.2 million, up 16% from the year-ago quarter, owing to a 10% increase in total demand. Jakafi's sales beat the Zacks Consensus Estimate of $717.5 million.
Opzelura (ruxolitinib) cream, approved for atopic dermatitis and vitiligo, generated $139.3 million in sales, which rose 52% year over year and surpassed the Zacks Consensus Estimate of $130.8 million. The year-over-year rise in sales was driven by continued growth in new patient starts and refills in the United States and increased contribution from the EU, driven by continued uptake in Germany and the launch in France.
The newly approved medicine Zynyz (retifanlimab-dlwr) generated sales of $0.69 million. The company obtained accelerated approval for Zynyz to treat metastatic or recurrent locally advanced Merkel cell carcinoma. The net product revenues of Iclusig were $29.7 million, up 7% year over year. The figure beat the Zacks Consensus Estimate of $28.1 million. Pemazyre generated $20.7 million in sales, reflecting a year-over-year decrease of 9%. The figure missed the Zacks Consensus Estimate of $22.2 million.
Minjuvi's revenues totaled $31.4 million, surging 277% from the prior-year quarter’s number, following the acquisition of the exclusive global rights to the drug in February 2024. The figure, however, missed the Zacks Consensus Estimate of $33.9 million. Incyte gained worldwide exclusive global rights for tafasitamab from MorphoSys AG, which is marketed as Monjuvi in the United States and as Minjuvi in the ex-U.S. markets in February.
Shares of Incyte have risen 4.6% year to date against the industry’s 3% decline.
Image Source: Zacks Investment Research
We remind investors that Jakafi is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets. Jakavi royalty revenues from Novartis for commercialization in ex-U.S. markets rose 20% to $115.7 million. Jakavi royalties beat the Zacks Consensus Estimate of $104.7 million.
Incyte also receives royalties from the sales of Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small-cell lung cancer. Its partner, Novartis, has exclusive worldwide development and commercialization rights for Tabrecta. The royalty revenues from the drug’s sales amounted to $5.9 million, up 43% year over year.
Olumiant’s (baricitinib) product royalty revenues from Eli Lilly (LLY - Free Report) totaled $34.8 million, up 17% year over year. The figure missed the Zacks Consensus Estimate of $35.2 million. Incyte has a collaboration agreement with Eli Lilly for Olumiant. The drug is a once-daily oral JAK inhibitor discovered by Incyte and licensed to LLY. It is approved for several types of autoimmune diseases.
Adjusted research and development expenses totaled $525.3 million, up 51% year over year. This increase was primarily due to the $100 million milestone payment made to MacroGenics during the third quarter of 2024 and continued investment in the company’s late-stage development assets.
Adjusted selling, general and administrative expenses were $277.3 million, up 15% from the prior year quarter’s number, primarily due to the timing of consumer marketing activities and that of certain other expenses. Incyte’s cash, cash equivalents and marketable securities totaled $1.8 billion as of Sept. 30, 2024, compared with $1.4 billion as of June 30, 2024.
INCY’s Updated 2024 Guidance
Incyte raised the 2024 revenue guidance for Jakafi. The company now expects Jakafi revenues in the range of $2.74-$2.77 billion compared with the earlier projection of $2.71-$2.75 billion.
Adjusted research and development expenses are now expected in the band of $2.395-$2.435 billion compared with the earlier projection of $2.295-$2.335 billion. Adjusted selling, general and administrative expenses are expected in the range of $1.115-$1.140 billion.
Incyte Corporation Price and Consensus
Incyte Corporation price-consensus-chart | Incyte Corporation Quote
Key Recent Developments
In August 2024, Incyte and partner Syndax Pharmaceuticals obtained FDA approval for axatilimab-csfr, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease after the failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. The candidate was approved under the brand name Niktimvo.
INCY’s Zacks Rank & Stock to Consider
Incyte currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Fate Therapeutics (FATE - Free Report) , carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Fate’s 2024 loss per share have narrowed from $1.74 to $1.73. Loss per share estimates for 2025 have narrowed from $1.71 to $1.69, during the same period. Year to date, shares of FATE have lost 23.3%.
Fate’s earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 18.22%.